Neuroendocrine tumors (NET) encompass a heterogeneous group of tumors demonstrating
varied clinical behavior. The field has recently witnessed several important developments …

The treatment landscape and biologic understanding of neuroendocrine tumors (NET) has
shifted dramatically in recent years. Recent studies have shown that somatostatin analogues …

Neuroendocrine tumors (NET) are frequently diagnosed late and not amenable to curative
surgery due to metastatic disease to the liver and lymph nodes. The disease is complex and …

Highlights•Novel therapeutic options are crucially needed for relatively rare but deadly
NETs.•Somatostatin analogs control tumor growth and symptoms in selected …

Although neuroendocrine tumors (NET) are a relatively rare malignancy, the reported
incidence is increasing, and some of the current treatment options are limited in their …

Low-to intermediate-grade neuroendocrine tumor (NET) constitutes a group of indolent
malignancies that share the capacity for secreting hormones and neuroamines. Until …

Neuroendocrine tumors (NETs) show low but increasing incidence and originate in multiple
organs, including the pancreas, midgut, caecum, rectum, appendix, colon, and lungs. Due to …

Opinion statement Well-to moderately differentiated neuroendocrine tumors (NET) are a
heterogeneous group of malignancies for which a range of therapeutic options have been …

Neuroendocrine tumors (NETs) are a group of tumors originating in various locations,
including the gastrointestinal tract, lung, and pancreas. Clinical trial design and disease …

Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse
neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract …